The transcription factor FoxP3 can fold into two dimerization states with divergent implications for regulatory T cell function and immune homeostasis

Graphical abstract

Highlights

- FoxP3 forms a head-to-head (H-H) dimer, instead of a domain-swap dimer
- H-H dimerization confers distinct DNA specificity and promotes Runx1 binding
- H-H dimerization is unique to Foxp3, providing functional specialization
- Disease mutation R337Q causes swap dimerization of FoxP3 and impairs its function

Authors

Fangwei Leng, Wenxiang Zhang, Ricardo N. Ramirez, ..., Alexander Y. Rudensky, Christophe Benoist, Sun Hur

Correspondence

sun.hur@crystal.harvard.edu

In brief

FoxP3 is an essential transcription factor for regulatory T cells and overall immunologic homeostasis. We show that the forkhead DNA-binding domains of FoxP3 form a unique head-to-head dimer. This is important for DNA and cofactor binding and provides functional specificity. Furthermore, a disease mutation inducing alternative dimerization impairs Foxp3 function.
The transcription factor FoxP3 can fold into two dimerization states with divergent implications for regulatory T cell function and immune homeostasis

Fangwei Leng,1,2,9 Wenxiang Zhang,1,2,9 Ricardo N. Ramirez,3,4 Juliette Leon,3,4 Yi Zhong,5,6 Lifei Hou,7 Koichi Yuki,7 Joris van der Veeken,8 Alexander Y. Rudensky,9 Christophe Benoist,3,4 and Sun Hur1,2,10,*

1Howard Hughes Medical Institute and Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, MA 02115, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
3Department of Immunology, Harvard Medical School, Boston, MA 02115, USA
4Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA 02115, USA
5Howard Hughes Medical Institute and Immunology Program, Sloan Kettering Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY, USA
6Shanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital, Boston, MA 02115, USA
8Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria
9These authors contributed equally
10Lead contact
*Correspondence: sun.hur@crystal.harvard.edu
https://doi.org/10.1016/j.immuni.2022.07.002

SUMMARY

FoxP3 is an essential transcription factor (TF) for immunologic homeostasis, but how it utilizes the common forkhead DNA-binding domain (DBD) to perform its unique function remains poorly understood. We here demonstrated that unlike other known forkhead TFs, FoxP3 formed a head-to-head dimer using a unique linker (Runx1-binding region [RBR]) preceding the forkhead domain. Head-to-head dimerization conferred distinct DNA-binding specificity and created a docking site for the cofactor Runx1. RBR was also important for proper folding of the forkhead domain, as truncation of RBR induced domain-swap dimerization of forkhead, which was previously considered the physiological form of FoxP3. Rather, swap-dimerization impaired FoxP3 function, as demonstrated with the disease-causing mutation R337Q, whereas a swap-suppressive mutation largely rescued R337Q-mediated functional impairment. Altogether, our findings suggest that FoxP3 can fold into two distinct dimerization states: head-to-head dimerization representing functional specialization of an ancient DBD and swap dimerization associated with impaired functions.

INTRODUCTION

The human genome is estimated to encode approximately 1,600 transcription factors (TFs). The vast majority of these TFs, however, utilize one of just 10 types of DNA-binding domains (DBDs) (Lambert et al., 2018), many of which display remarkably conserved and narrow sequence specificity (Nitta et al., 2015). The apparent simplicity in DBD composition is in sharp contrast to the complex network of genes they control. How DBDs can divergently evolve to carry out distinct functions remains incompletely understood (Badis et al., 2009; Joilma et al., 2015; Reiter et al., 2017).

One of the largest families of DBDs in eukaryotes is the forkhead DBD, which commonly displays a winged-helix fold and recognizes the consensus sequence known as forkhead motif (FKHM)—TGTTTAC (Dai et al., 2021). There are about 50 forkhead TFs in humans, which play important roles in key biological processes—including development, reproduction, aging, and immunity (Benayoun et al., 2011; Hannenhalli and Kaestner, 2009). Some forkhead TFs function as pioneering TFs that can directly recognize DNA sequences within the condensed chromatin and open its structure with the help of chromatin modifiers (Drouin, 2014), whereas others utilize the pre-existing chromatin landscape without dramatically altering the chromatin structure (Samstein et al., 2012). This suggests that there is great functional diversity even within the forkhead TF family not only in the biological processes they control but also in the molecular mechanisms they employ.

FoxP3 is a forkhead TF that plays a critical role in the development of regulatory T cells (Tregs), a branch of CD4+ T cells that suppresses immune functions to prevent autoimmunity and excessive inflammation (Bennett et al., 2001; Brunkow et al., 2001; Fontenot et al., 2003; Hori et al., 2003). Certain mutations in FoxP3 lead to the multiorgan autoimmune disease immune dysregulation, polyendocrinopathy, enteropathy, and X-linked (IPEX) syndrome in human and similar autoimmune conditions.
in mice (Bennett et al., 2001; Brunkow et al., 2001; Chatila et al., 2000; Gambineri et al., 2008; Rubio-Cabezas et al., 2009; Tanaka et al., 2005; Wildin et al., 2001). FoxP3 is key to determining and maintaining Treg cell identity by transcriptionally up- or down-regulating hundreds of genes (Kwon et al., 2017; van der Veeken et al., 2020). Despite its importance in immune homeostasis, molecular functions of FoxP3 remain poorly understood. For example, it is highly debated whether FoxP3 is a transcriptional activator, suppressor, or both depending on the target genes (Arvey et al., 2014; Kwon et al., 2017; Li et al., 2007; Zemmour et al., 2021; Zheng et al., 2007). Moreover, which genes affected by FoxP3 are direct targets versus those regulated indirectly is not understood (Ramirez et al., 2022; van der Veeken et al., 2020; Zemmour et al., 2021). It is also unclear how FoxP3 alters the target gene expression as FoxP3 binds predominantly to genomic loci that have pre-established chromatin accessibility and induces little change in the accessibility of the bound sites (Samstein et al., 2012; van der Veeken et al., 2020; Yoshida et al., 2019).

Equally puzzling are the biochemical and structural properties of FoxP3. FoxP3 contains an N-terminal proline-rich region that recruits a variety of cofactors, zinc finger (ZF) that likely binds DNA, and coiled coil (CC) that forms an antiparallel dimer (Song et al., 2012; Figure 1A). Following the CC is a long linker that recruits the cofactor Runx1 (Ono et al., 2007) (referred to here as Runx1-binding region [RBR]) and the forkhead domain responsible for DNA binding. Among these domains, the forkhead domain is most frequently mutated in IPEX patients and has been most extensively studied (Barzaghi et al., 2012; Huang et al., 2020). Previous studies report that isolated FoxP3 forkhead folds into an unusual domain-swap dimer that drastically differs from the winged-helix monomeric structure typical of forkhead DBD (Bandukwala et al., 2011; Chen et al., 2015). FoxP1 also expressed in Treg cells (Ghosh et al., 2018; Konopacki et al., 2019), and FoxP2 are closely related to FoxP3 and can also form domain-swap dimers (Chu et al., 2011; Stroud et al., 2006). These observations have led to the widely accepted notion that FoxP TFs may have evolved to adopt the swap-dimeric fold. However, a peptide that binds FoxP3 ZF-CC can disrupt FoxP3 dimerization, inconsistent with the domain-swap model of forkhead (Lozano et al., 2017). FoxP2 was also crystalized as a non-swap monomer as well as the domain-swap dimer (Stroud et al., 2006; Wu et al., 2006), further raising the question about the physiologically relevant structure of the FoxP forkhead domains. More globally, the overall architecture of FoxP3 beyond its DBD and how FoxP3 differs from other closely related TFs to carry out its unique function also remains unclear.

We here showed that FoxP3 forkhead, as well as those of other FoxP TFs, folded into the winged-helix, non-swap conformation, and that this required the presence of the RBR linker. Individually folded forkhead domains then formed a head-to-head (H-H) dimer upon DNA binding. Although other FoxP TFs also utilized their RBR-like linkers for monomeric folding, H-H dimerization was unique to FoxP3 and imparted distinct functions to FoxP3. Our functional data provide new insights into the pathogenic mechanism for IPEX mutations and a new framework of understanding for FoxP3 functions.

RESULTS

FoxP3 preferentially binds two forkhead consensus motifs in inverted repeat

We first attempted purifying full-length mouse FoxP3 protein from E. coli but found it heavily degraded in the N-terminal Pro-rich region. This was consistent with multiple structural predictions (e.g., AlphaFold2, Jpred4), suggesting that the N-terminal region is intrinsically disordered (Drozdzetskiy et al., 2015; Jumper et al., 2021). We therefore purified an N-terminal truncation variant (FoxP3AN) harboring ZF, CC, RBR, and forkhead domains (Figures 1A and S1A). We also purified FoxP3RBR-forkhead and FoxP3forkhead for comparison. Consistent with the previous report that FoxP3forkhead constitutively forms a swap dimer (Bandukwala et al., 2011), FoxP3forkhead was dimeric as measured by size-exclusion chromatography-coupled multangle light scattering (SEC-MALS) (Figure 1B). We used FoxP3 fused with the protein tag NusA (60 kDa) to improve accuracy of molecular weight estimation by SEC-MALS. Unlike FoxP3forkhead, FoxP3RBR-forkhead was monomeric (Figure 1B), which was incompatible with the model that the forkhead domain forms a swap-dimeric structure. FoxP3AN was a dimer but disruption of the CC dimerization by a mutation in the CC dimeric interface (L241D) (Song et al., 2012) converted it to a monomer (Figure 1B), suggesting that FoxP3 dimerization was exclusively mediated by CC and that this forkhead domain within the FoxP3AN construct was a monomer.

Given that the observed differences in the oligomeric state of FoxP3 forkhead depended on other domains, we postulated that there may be different conformations of forkhead. We next asked how these different conformations affected DNA binding. We first examined DNA containing only a single FKHM (sFKHM, 22 or 31 bp) by electrophoretic mobility shift assay (EMSA) but found that binding was nearly undetectable for all three proteins of FoxP3AN, FoxP3RBR-forkhead, and FoxP3forkhead up to 0.8 μM (Figures 1C, S1E, and S1F). A tandem repeat of FKHM is suggested to increase FoxP3 affinity (Koh et al., 2009), prompting us to examine the potential effect of tandem repeats of FKHM, both direct repeats (DRs) and inverted repeats (IRs), with various gap sizes. FoxP3AN had a strong preference for IR-FKHM with a 4-nt gap (IR-FKHM4) (Figures 1C and 1D), but not for any DR-FKHM, regardless of the gap size (Figures S1B and S1C). The same DNA specificity was observed for full-length FoxP3 expressed in 293T cells, suggesting that FoxP3’s preference for IR-FKHM4 is independent of the source of the protein (Figure S1D).

FoxP3RBR-forkhead also displayed the same preference for IR-FKHM4 (Figure S1E), whereas FoxP3forkhead did not (Figure S1F). FoxP3forkhead was less efficient in DNA binding than FoxP3AN and FoxP3RBR-forkhead (Figure 1C, last 6 lanes, and Figures S1E and S1F). Considering that the preference for IR-FKHM4 was observed only with FoxP3AN and FoxP3RBR-forkhead, which harbored monomeric forkhead, but not with swap-dimeric FoxP3forkhead, we suspected that the different DNA selectivity was a direct consequence of different forkhead conformations. In fact, modeling suggested that the two swap dimers could not simultaneously occupy two FKHM’s in IR-FKHM4 (Figure S1G), explaining why FoxP3forkhead did not display the same preference for IR-FKHM4 as with FoxP3AN and FoxP3RBR-forkhead. These
Figure 1. Overall architecture of FoxP3

(A) Domain architecture of FoxP3N, FoxP3RBR-forkhead, and FoxP3forkhead. ZF, zinc finger; CC, coiled coil; RBR, Runx1-binding region.

(B) SEC-MALS of truncation variants of FoxP3. Experimentally determined mass values are shown in parentheses on the graphs. Theoretical values are shown in the table below.

(C) EMSA of FoxP3N or FoxP3forkhead (0, 0.4, and 0.8 μM) using four DNA oligos (0.2 μM) with different FKHM arrangements. Sybr Gold stain was used to visualize DNA. Although FoxP3N binds DNA predominantly as a dimer (*), a small population of higher-order oligomer (**) was also seen.

(D) EMSA of FoxP3N (0, 0.4, and 0.8 μM) with DNA containing IR-FKHM (0.2 μM) with varying gap sizes.

(E) Crystal structure of Foxp3N in complex with IR-FKHM4g DNA. Two non-swap FoxP3 monomers form a head-to-head dimer through the RBR loop. ZF and CC were present in the crystal (see Figure S2E) but were not resolved. The helix 3 (H3) and wing 1 that are characteristics of the canonical forkhead structure are indicated with circles.

Data in (B–D) are representative of at least three independent experiments. See also Figures S1 and S2.
results indicated that FoxP3 forkhead in more native domain architecture (FoxP3\textsuperscript{AN} and FoxP3\textsuperscript{RBR-forkhead}) is not in the swap-dimeric conformation and that the true conformation of FoxP3 is the key to understanding its DNA specificity.

**Overall architecture of FoxP3**

We co-crystallized FoxP3\textsuperscript{AN} in complex with IR-FKHM\textsuperscript{4g}. We tested multiple truncation variants for improved solubility and crystalizability and found deletion of residues 277–304 and 277–314 within the RBR linker necessary (FoxP3\textsuperscript{AN} and FoxP3\textsuperscript{AN} in Figure S2A). Both constructs displayed preferential binding for IR-FKHM\textsuperscript{4g} as with FoxP3\textsuperscript{AN} (Figure S2B). Crystals of FoxP3\textsuperscript{AN} and FoxP3\textsuperscript{AN} diffracted to 4.0 and 3.1 Å, respectively (Table S1). Our attempt to solve the structure using the swap-dimeric FoxP3\textsuperscript{forkhead} as the molecular replacement template failed. However, using non-swap monomeric structures of forkhead from other TFs (such as FoxN1; Newman et al., 2020), we identified unambiguous solutions and obtained final models (see STAR Methods and Table S1).

The structures of FoxP3\textsuperscript{AN} and FoxP3\textsuperscript{AN} were similar and revealed several notable features. First, both FoxP3\textsuperscript{AN} and FoxP3\textsuperscript{AN} formed the winged-helix, non-swap conformation, rather than the swap dimer (Figures 1E and S2C). As with other forkhead TFs with the winged-helix fold (Dai et al., 2021), FoxP3 inserted the signature helix 3 (H3) into the major groove forming a sequence-specific interaction with DNA, whereas wing 1 formed additional contact with the DNA phosphate backbone. The potential source of the discrepancy between our structure versus the previous swap dimer structure and the functional implications of the new structure are discussed in Figure 2. Second, the structure also revealed that FoxP3\textsuperscript{AN} bound IR-FKHM\textsuperscript{4g} as a H–H dimer, where each monomer occupied a sFKH (Figure 1E). In this configuration, the forkhead dimer bound one side of the DNA, occupying two consecutive major grooves. DNA was bent ~25° (Figure 1E), although the degree of bending differed slightly between the FoxP3\textsuperscript{AN} and FoxP3\textsuperscript{AN} structures (Figure S2D). H–H dimerization of FoxP3 are discussed in Figures 3 and 4. Third, although structures of forkhead and part of RBR (residues 322–336) were resolved, the rest of RBR (residues 262–321), CC and ZF were not seen in either crystal structure. SDS-PAGE analysis, however, showed that the protein was intact in the crystal (Figure S2E), suggesting that RBR (262–321), ZF, and CC were flexible or adopt heterogeneous conformations in the crystal. Although ZF within the FoxP3\textsuperscript{AN} construct made a significant contribution to DNA binding (Figure S2F), isolated ZF-CC on its own displayed limited DNA affinity (Figure S2G). Thus, we propose an overall architecture of FoxP3-DNA complex, where the H–H dimer of FoxP3\textsuperscript{RBR-forkhead} forms the primary contact with DNA, whereas two ZFs flexibly tethered through CC and RBR form secondary contacts with nearby sites on DNA without a fixed location relative to FoxP3\textsuperscript{RBR-forkhead} (Figure S2H).

**FoxP3 forkhead exists in the non-swap monomeric conformation in the presence of RBR**

Our finding that the forkhead domain within FoxP3\textsuperscript{AN} formed the non-swap monomeric conformation contradicted the previous report that isolated FoxP3\textsuperscript{forkhead} exists as a domain-swap dimer (Bandukwala et al., 2011). We thus investigated the potential source of the discrepancy and which of the two is functionally relevant. The primary difference between the swap dimer and non-swap monomer was in the helix 2 (H2) and helix 4 (H4), which in the non-swap monomer were separated by a turn at residue A372 (Figure 2A, left). In contrast, in the swap dimer, H2 and H4 are merged into a single extended helix (H2+4) (Bandukwala et al., 2011; Figure 2A, right). The swap dimer interface on H2+4 contains a patch of hydrophobic residues (W366, F367, M370, F371, Y373, and F374), which in the non-swap conformation were buried within the folded forkhead core or protected by RBR (Figure 2A). This suggested that RBR may be responsible for stabilizing the non-swap conformation by protecting otherwise solvent exposed hydrophobic residues. In other words, deletion of RBR and subsequent exposure of hydrophobic residues may drive the swap dimerization. Consistent with this view, FoxP3 forkhead was monomeric in the presence of RBR (as in FoxP3\textsuperscript{AN} and FoxP3\textsuperscript{RBR-forkhead}), whereas isolated FoxP3\textsuperscript{forkhead} without RBR formed a swap dimer (Figure 1B).

To further examine which of the two conformations is physiologically relevant, we employed a protein engineering approach with the focus on residue 372 at the junction of H2 and H4 (Figure 2A). The residue 372 is unique in its potential to switch the forkhead conformation between swap and non-swap structures (Bandukwala et al., 2011). We hypothesized that replacement of Ala at 372 by an amino acid with low helix propensity, such as Pro, Gly, or Ser, would force separation of H2 and H4 and convert FoxP3\textsuperscript{forkhead} to the monomeric conformation. As predicted, A372P, A372G, and A372S all biased isolated FoxP3\textsuperscript{forkhead} from dimeric to largely monomeric state, albeit to varying degrees (Figure 2B). Protein crosslinking analysis also suggested that all three mutations suppressed swap dimerization (Figure S3A). We next examined the impact of the A372 mutations on the transcriptional activity of FoxP3, as measured by the levels of CTLA4 and CD25 (two Treg cell markers) upon expression of FoxP3 in CD4+ T cells. If FoxP3 functions require the swap-dimeric structure, all three mutations of A372 should result in loss of function. The result showed that although A372P partially impaired the transcriptional activity of FoxP3, as previously reported (Bandukwala et al., 2011), A372G and A372S had little impact (Figure 2C), arguing against the requirement for domain-swap dimerization in FoxP3 function. The negative impact of A372P appeared independent of its ability to suppress swap dimerization; introduction of A372P in FoxP3\textsuperscript{RBR-forkhead}, which already existed as a non-swap monomer, did not alter its monomeric state (Figure 2D) but negatively affected its DNA affinity (Figure 2E) and the protein melting curve (Figure S3B). Such negative impact was not observed with A372G and A372S (Figures 2E and S3B). Collectively, the results with A372G and A372S suggested that swap dimerization is not required for FoxP3 functions.

We next asked whether the impact of RBR on forkhead folding is conserved in other FoxP TFs, which also contain Ala at position equivalent to 372 (Figure S3C) and form domain-swap dimers when expressing forkhead domains in isolation (Chu et al., 2011; Stroud et al., 2006). FoxP1, FoxP2, and FoxP4 all contain RBR-like linkers between CC and FKH. We expressed FoxP1/2/4 proteins equivalent to the FoxP3\textsuperscript{RBR-forkhead} construct and found that FoxP1/2/4 proteins were monomeric when purified with RBR-like linkers (Figure 2F). Thus, the role of RBR or RBR-like linkers in stabilizing the non-swap conformation is
conserved in all FoxP TFs. These results further supported the notion that the non-swap conformation is the physiologically relevant form for all four members of FoxP TFs.

**H-H dimerization of forkhead is unique to FoxP3 and is important for DNA binding**

Our structure showed that individual FoxP3 forkhead folded into a monomer, but this monomer formed a H-H dimer when bound to DNA containing IR-FKHM (Figure 1E). H-H dimerization was mediated by part of RBR (residues 321–336, referred to as the RBR loop), which interacted with the RBR loop and forkhead from the other subunit (Figure 3A). Electron density for the RBR loop was not as well defined as other parts of the protein (Figure S4A), suggesting conformational flexibility in the H-H interface. Residues located within the RBR loop and near the interface were highly hydrophobic (Figure 3A), suggesting that...
Figure 3. RBR loop-mediated H-H dimerization is important for and unique to FoxP3

(A) Top view of the FoxP3 H-H dimer. The RBR loop forms the interface through the RBR-RBR and RBR-forkhead interactions. Hydrophobic residues (Cα) at or near the interface are shown in blue or purple spheres. K332 and R347 are shown in orange spheres.

(B) DNA-binding activity of H-H interface mutants. Biotinylated DNA with IR-FKHM4g was used to pull-down FoxP3 ectopically expressed in 293T cells.

(C) Transcriptional activity of the H-H interface mutants. Experiments were performed as in Figure 2 C.

(D) T cell suppression assay of FoxP3. CD4+ T cells were retrovirally transduced to express FoxP3 and their suppressive effect on proliferation of the responder T cells was examined. Shown is the representative histogram depicting the CFSE dilution profile of responder T cells cultured with FoxP3-expressing suppressor cells at a ratio of 1:2 (suppressors:responders).

(legend continued on next page)
H-H dimerization was driven by a collection of hydrophobic interactions, reminiscent of “fuzzy” interactions shown for other TFs (Pricer et al., 2017; Tuttle et al., 2021). The RBR loop was also involved in crystallographic packing (Figures S4A and S4B), likely involving similarly fuzzy, hydrophobic interactions. Thus, the hydrophobic nature of the RBR loop may enable multiple types of protein–protein interactions beyond H-H dimerization (to be discussed in Figure 6).

To examine whether the H-H dimerization is simply a result of binding IR-FKHM11 or accounts for FoxP3’s preference for IR-FKHM11, we introduced single-point mutations in or near the H-H dimeric interface in both RBR and forkhead. These included aforementioned hydrophobic residues and basic residues, including an IPEX mutation R347H (Gamberini et al., 2008; Figure 3A). Consistent with the view that H-H dimerization is the cause, rather than the consequence, of IR-FKHM11 binding, the H-H interface mutations impaired FoxP3’s affinity for IR-FKHM11 DNA, as measured by biotinylated DNA pull-down (Figure 3B). Some residues in the RBR loop, such as F331 and H334, were not located at the interface but still played important roles, suggesting that these residues may shape the RBR loop and thereby indirectly involved in H-H dimerization. The interface mutations also impaired the cellular functions of FoxP3, as measured by induction of CD25 and CTLA4 (Figure 3C) or by T cell suppression assay (Figure 3D).

Note that the loss of H-H dimerization did not necessarily lead to domain-swap dimerization; F331D, R347H, and W348D FoxP3RBR-forkhead were impaired in H-H dimerization and yet were stable as a monomer (Figure S4C). Thus, although the non-swap conformation was prerequisite for H-H dimerization, H-H dimerization was not required for non-swap conformation. Additionally, these data showed that H-H dimerization was important for both DNA binding and FoxP3’s transcriptional activity.

Given the importance of H-H dimerization for FoxP3, we next asked whether H-H dimerization also occurred with other FoxP TFs. We compared FoxP3RBR-forkhead binding with IR-FKHM versus sFKHM, since H-H dimerization would manifest in preferential binding of IR-FKHM. In contrast to FoxP3, FoxP1/2/4 equally bound IR-FKHM11 and sFKHM (Figure 3E), and this was independent of the IR-FKHM gap size (Figure S4D). Additionally, the native gel migration rate of the FoxP1/2/4 complexes were similar, regardless of whether on IR-FKHM11 or sFKHM — another indication that they bound both DNAs as a monomer (Figure 3E). These results suggested that H-H dimerization did not occur to other FoxP TFs. Perhaps, reflecting this difference in the ability to form a H-H dimer, the RBR sequence of FoxP3 differs from the equivalent linker in other FoxP TFs (Figure 3F). Altogether, our results suggested that H-H dimerization was an important and a unique feature of FoxP3 and imparted distinct DNA specificity to FoxP3.

H-H dimerization is important for FoxP3 binding to suboptimal DNA sequence

We next asked whether H-H dimerization of FoxP3 was limited to IR-FKHM11 or whether this also occurred when FoxP3 bound suboptimal, low-affinity sequences. This was an important question because many TFs were known to bind suboptimal sequences in cells (Pfeifer et al., 1987; Segal et al., 2008), likely driven by cooperative binding with cofactors (Reiter et al., 2017). In fact, FoxP3 functions together with other cofactors (Kwon et al., 2017; Rudra et al., 2012; Wu et al., 2006), many of which have their own DBDs and may assist FoxP3-DNA interaction in cells (Samstein et al., 2012; Wu et al., 2006). One of the best-characterized cofactors for FoxP3 is NFAT, whose DBD (Rel homology region [RHR]) interacts directly with FoxP3 forkhead (Bandukwala et al., 2011). Although the previous structure of FoxP3 in complex with NFAT was determined with the swap-dimeric FoxP3forkhead, the NFATRHR interface is nearly identical in both the swap and non-swap conformations, making both conformations compatible with NFAT binding (Figure S5A). As such, the non-swap FoxP3ΔN also showed cooperative DNA binding with NFAT when the NFAT-binding site was 3 nt upstream of FKHM, the requirement for NFAT-FoxP3 interaction (Figure 4A). Both FoxP3 and NFAT bound IR-FKHM11 better than sFKHM. Furthermore, both FoxP3 and NFAT bound better in the presence of the other protein than in its absence (Figures 4A, S4B, and S5C), suggesting that they mutually assist each other. The effect of NFAT on FoxP3 was more evident with sFKHM than with IR-FKHM11, consistent with the notion that FoxP3 alone can bind IR-FKHM11 efficiently, alleviating requirement of cofactor assistance. When H-H interface mutations (F331D and W348D) were introduced to FoxP3, DNA affinity was reduced for both IR-FKHM11 and sFKHM, with or without NFAT (Figure 4B). This suggested that H-H dimerization was important even when FoxP3 bound suboptimal DNA assisted by the cofactor NFAT.

To more directly examine whether FoxP3 formed the H-H dimer when it bound suboptimal DNA sequence, we examined FoxP3 footprint using a restriction enzyme protection assay. We chose IR-FKHM11 as a suboptimal DNA because it allowed predicting two distinct binding modes. In one mode, two FoxP3 molecules bridged by CC could occupy two FKHMs separated by the 11-nt gap without forming a H-H contact (Figure 4C, right panel i). In the alternative mode, FoxP3 could bind IR-FKHM11 as a H-H dimer, occupying only one of the FKHMs — most likely FKHM near the NFAT site (FKHM1) — and the suboptimal sequence 4 nt away from FKHMI, leaving the second FKHMI (FKHM2) unoccupied (Figure 4C, right panel ii). To distinguish between the two modes, we placed the BamHI restriction site near FKHMI to examine the occupancy of FKHMI2 (Figure 4C). The XhoI and EcoRI sites were also introduced to report FKHMI1 occupancy and DNA-binding specificity, respectively.

We first tested an equivalent construct with IR-FKHM11. Under the condition where FoxP3ΔN occupied DNA in a
sequence-specific manner (i.e., the XhoI site was fully protected while the EcoRI site was fully accessible), the BamHI site was protected by FoxP3 (Figure 4D, left half), consistent with the crystal structure where both FKHM1 and FKHM2 were occupied by FoxP3 H-H dimer. In contrast, the BamHI site of IR-FKHM11g was largely accessible, although DNA was fully occupied by FoxP3 (as evidenced by the XhoI site protection) (Figure 4D, right half). Unlike FoxP3<sup>ΔN</sup>, FoxP3<sup>Forkhead (A372S)</sup>, which could not form a H-H dimer, showed no difference between IR-FKHM<sup>11g</sup> and IR-FKHM<sup>11g</sup> in the BamHI site protection (Figure S5D). These results suggested that FoxP3<sup>ΔN</sup> maintained the H-H dimeric structure when binding IR-FKHM<sup>11g</sup> as well as...
Together with the data in Figure 4B, they further supported the notion that FoxP3 binds DNA as a H-H dimer, regardless of the DNA sequence.

H-H dimerization enables FoxP3 to recognize diverse DNA sequences

Our data above suggested that H-H dimerization was an important mode of DNA binding for FoxP3, and this greatly influenced its DNA sequence specificity in vitro. To assess the impact of H-H dimerization on FoxP3-DNA interaction in Treg cells, we investigated previously reported FoxP3 ChIP-seq data for potential enrichment of the IR-FKHM sequence (Kitagawa et al., 2017; Samstein et al., 2012).

De novo motif analysis of 5,000 consensus FoxP3 ChIP-seq sequences did not identify IR-FKHM (p value < 10^{-9}), although sFKHM was identified in these peaks. As an alternative strategy, we separately analyzed 548 FoxP3-bound peaks containing an FKHM and counted the number of instances of an inverted FKHM (Figure 5A). Motif occurrences were counted if p value < 10^{-5} and score greater than 12.

FoxP3 interaction with DNA harboring FKHM paired with non-consensus motifs (seq1-4). Purified MBP-FoxP3DN was mixed with DNA oligos and was subjected to MBP pull-down, followed by native PAGE analysis of co-purified DNA. Right: MBP-FoxP3DN was used for comparison.

FoxP3 interaction with DNA harboring potential FoxP3-binding sequences paired with FKHM. These sequences were chosen from five loci in the major allele where mutations were associated with reduced FoxP3 occupancy.

FoxP3 interaction with DNA harboring natural sequences from loci I and IV (see D).

Alignment of FoxP3-compatible sequences examined in this figure. Sequence deviation from FKHM was highlighted with underscores.

See also Figure S6.
repeats with a gap size ranging from 1 to 21 nt; no enrichment of 4-nt spacing was observed (Figure 5B). One explanation for this lack of IR-FKHM enrichment could be that FoxP3, like other TFs (Nakagawa et al., 2013), utilizes many distinct suboptimal sequences in the presence of cofactors. H-H dimerization of FoxP3 may further increase the diversity of such suboptimal sequences it can bind, as shown with other dimeric TFs (Arnett et al., 2010; Jiang et al., 2019).

To examine the possibility of diverse sequence recognition by the FoxP3 H-H dimer, we examined FoxP3 binding to four non-consensus motifs (seq1-4) that were previously shown to bind other forkhead TFs (Nakagawa et al., 2013; Rogers et al., 2019). These non-consensus sequences were paired with FKHM in the inverted orientation with a 4-nt gap (Figure 5C, top). FoxP3 bound FKHM paired with seq1/2/3 significantly more efficiently than sFKHM (Figure 5C, bottom left). In comparison, FoxP2 showed similar binding to all DNA, regardless of the sequence paired with FKHM (Figure 5C, bottom right). When seq1-3 were paired with themselves instead of FKHM, FoxP3 binding was undetectable (Figure S6C), indicating that at least one FKHM was necessary. Similar results were obtained using binding was facilitated by H-H dimerization, H-H interface mutation and non-swap conformation, we asked whether some IPEX mutations are caused by errors in these features. Note that the non-swap conformation is a precondition for H-H dimerization, and thus, any mutation that alters non-swap folding would impair all aspects of FoxP3 function including H-H dimerization, DNA binding, and Runx1 binding. Among the

**H-H dimerization is important for Runx1 binding**

Given that H-H dimerization was largely mediated by RBR and that RBR recruits Runx1 (Ono et al., 2007), we next asked what effect H-H dimerization had on Runx1 binding. Our structure showed that H-H dimerization created a large hydrophobic surface that could mediate protein-protein interaction, as judged by their involvement in crystallographic packing (Figure S4B). Given that FoxP3-interacting region of Runx1 (residue 371–451) also is highly hydrophobic (Figure 6A), we asked whether the hydrophobic surface of FoxP3 RBR serves as a cofactor docking site for Runx1.

Using purified recombinant Runx1 (Runx1\(^{\Delta N}\), residue 371–451) and FoxP3\(^{\text{RBR-forkhead}}\), we confirmed that their interaction was direct (Figure 6B). We also found that this interaction was enhanced in the presence of DNA with IR-FKHM (Figure 6B), the condition that promoted H-H dimerization. The Runx1-FoxP3 interaction was not enhanced by DNA harboring sFKHM, further supporting the notion that H-H dimerization was important for Runx1 binding. Since Runx1\(^{\Delta N}\) did not contain a DBD, the observed dependence of Runx1-FoxP3 interaction on IR-FKHM was unlikely due to DNA-mediated bridging. Using full-length Runx1 and FoxP3 overexpressed in 293T cells, we also confirmed that their association depended on nucleic acids, as the benzozonea treatment impaired their co-immunoprecipitation (coIP) (Figure 6C). Consistent with the idea that Runx1 binding was facilitated by H-H dimerization, H-H interface mutations reduced Runx1-FoxP3 coIP (Figure 6D). Together, these data suggested that FoxP3 harnessed its H-H dimerization capability not only to alter DNA sequence specificity but also to recruit Runx1.

**IPEX mutation R337Q induces swap dimerization and impairs FoxP3 functions**

Given our findings supporting the importance of H-H dimerization and non-swap conformation, we asked whether some IPEX mutations are caused by errors in these features. Note that the non-swap conformation is a precondition for H-H dimerization, and thus, any mutation that alters non-swap folding would impair all aspects of FoxP3 function including H-H dimerization, DNA binding, and Runx1 binding. Among the
IPEX-associated mutations of FOXP3, R337Q attracted our attention as it is located near the end of RBR (Rubio-Cabezas et al., 2009; Figure 1A), which was involved in both non-swap conformation and H-H dimerization. Additionally, R337 directly contacted DNA in our non-swap structure but is far away from DNA in the swap-dimeric structure (Figure 7A), a feature that could further help distinguish between the two forkhead conformations.

To better analyze the effect of R337Q in Treg cells in vivo, we generated by CRISPR-Cas9 germline mutagenesis a mutant mouse line carrying the R337Q mutation in the endogenous Foxp3 locus (Figure 7B). Young male mice hemizygous for the mutation were viable, with no sign of wasting disease or overt dermatitis or intestinal pathology, differing from full FoxP3 deficiencies (Fontenot et al., 2003; Godfrey et al., 1991), although reduced weight gain and dermatitis did appear in older R337Q animals. In addition, they presented significant splenomegaly and lymphadenopathy (Figure 7B) and an increase in the level of activated (CD44+) T conventional (Tconv) cells (Figure 7C), suggesting a partial loss of Treg cell functionality. The proportion of FoxP3+ Treg cells and their activated (CD44+) fraction also increased in R337Q mice (Figure 7D), a compensatory phenotype previously observed in partial FoxP3 deficiencies (Kwon et al., 2018; Van Gool et al., 2019). R337Q Treg cells also showed decreased levels of CD25 and FoxP3, as well as CTLA4, characteristic of FoxP3 hypomorphs (Figures 7E and 7F), all indicative of partial FoxP3 dysfunction. Thus, the R337Q mutation impaired Treg fitness, with a repercussion in the control of CD4+ T cell homeostasis, although not as radical as the typical scurfy phenotype usually seen with the complete Foxp3 deficiencies.

We next introduced R337Q in recombinant protein and analyzed its impact on the biochemical properties of FoxP3. R337Q was purified as a dimer, which differed from monomeric WT FoxP3 RBR-forkhead (Figure 7G). Thermal stability of R337Q was also lower than that of WT but was rescued by A372S (Figure 7G). R337Q reduced DNA affinity, whereas A372S partially restored it (Figure 7H). To examine whether R337Q in fact existed in the domain-swap dimer in cells and whether this conformation accounted for the functional impairment of R337Q, we measured five activities of FoxP3 expressed in 293T or CD4+ T cells. These were (1) DNA binding (Figure 7I), (2) sequence preference for IR-FKHM over sFKHM (Figure 7J), (3) Runx1 binding (Figure 7K), (4) transcriptional activity (Figures 7L and S7B), and (5) T cell suppression activity (Figure 7M). All five activities, which depended on the non-swap conformation, were impaired upon R337Q mutation and were largely rescued by A372S. The incomplete rescue likely reflects the role of R337 not only in stabilizing the non-swap conformation but also in direct DNA binding, as our Foxp3 structure and DNA-binding assay suggested (Figures 7A and 7H). Collectively, these data supported the notion that functional impairment by the R337Q mutation is largely mediated by its induction of the domain-swap conformation, although its role in direct DNA binding also contributes.

Other IPEX mutations near the H2/H4 junctions can also cause folding errors

The impact of R337Q on FoxP3 folding was at first unexpected as R337 is on the protein surface, and folding errors are often associated with mutations in protein cores. R337, in our
Figure 7. IPEX mutation R337Q induces swap dimerization and impairs FoxP3 functions

(A) Location of R337 in the crystal structures of swap dimeric and non-swap monomeric FoxP3. R337 interacts with DNA and Y373 only in the non-swap conformation.

(B) Abnormal immune homeostasis in 8-week-old R337Q male mice, generated by CRISPR mutagenesis of Foxp3. Bottom left: a representative picture comparing the spleens and inguinal lymph nodes of R337Q mutant mice and their WT littermates. Bottom right: spleen weights.

(C) Fraction of activated (CD44+) conventional T (Tconv) cells among CD4+ T cells in the spleen and the colonic lamina propria of WT and R337Q mutant mice.

(D) Foxp3+ Treg in the spleen and the colonic lamina propria of R337Q mutant mice in comparison with their WT littermates. Left: Treg fraction among TCRβ+CD4+ T cells. Right: Treg activation status assessed by the marker CD44+.

(E) CD25/FoxP3 cytometry plots of spleen TCRβ+CD4+ T cells from WT and R337Q mutant mice.

(F) Quantification of CD25, CTLA4, and FoxP3 by flow cytometry (MFI) in TCRβ+CD4+Foxp3+ spleen Tregs of R337Q mutant mice and WT littermates.

(G) SEC-MALS of NusA-tagged FoxP3 RBR-forkhead.
structure, was in close proximity to Y373, another surface residue mutated in IPEX patients (Y373V) (Tanaka et al., 2005). We first confirmed that Y373V impaired FoxP3 transcriptional function (Figure S7C). Analysis of other forkhead protein structures (in the non-swap conformation) showed that residues equivalent to R337 and Y373 were often in close proximity with the potential of forming pi-cation or pi-pi interactions (Figure S7D). This observation prompted us to ask whether Y373 also played an important role in stabilizing the non-swap conformation. Recombinant Y373V FoxP3RBR-forkhead protein displayed a broad elution profile in size-exclusion chromatogram with the peak molecular weight corresponding to a tetramer (Figure S7E), which was indicative of folding defects, albeit somewhat differently than R337Q.

To further examine whether similar folding errors can account for IPEX pathogenesis, we investigated seven additional IPEX mutations in the forkhead domain: I346T, R347H, I363V, M370I, F371C, F367L, and F374C (Figures S7F and S7G). Of these mutations, we found that I346T, M370I, and F374C shifted the size-exclusion elution profile of FoxP3RBR-forkhead from a monomer to aggregate, likely indicating folding errors (Figure S7F). Mapping of the folding-disruptive mutations, including R337Q and Y373V, onto our crystal structure (Figure S7H) revealed that all but I346T were located near the junction of H2 and H4, the key site for the domain-swap to non-swap conversion (Figure 2A). These observations suggested that the H2/H4 junction may be the “Achilles’ heel” for proper folding of FoxP3, and such folding errors involving the H2/H4 junction may be a common etiology for IPEX.

**DISCUSSION**

To better understand how FoxP3 utilizes the common DBD forkhead to function as a unique TF for Treg determinism, we characterized FoxP3 using a combination of structural biology, biochemistry, and functional assays. Our study revealed that unlike previous reports with isolated forkhead DBD (Bandukwala et al., 2011), FoxP3 forkhead folded into a non-swap monomer and utilized the appendage domain RBR to form a H-H dimer for DNA binding. This requirement for H-H dimerization distinguishes FoxP3 from other forkhead TFs characterized to date, including FoxP1/2/4, which binds DNA as individual DBDs (Dai et al., 2021). As a result, FoxP3 read DNA sequence spanning ~18 bp, rather than 7 bp as monomeric forkhead would. Although FoxP3 strongly favored IR-FKHM over a sFKHM, it also recognized diverse and distinct non-consensus sequences beyond IR-FKHM. FoxP3 H-H dimerization also facilitated its interaction with the essential cofactor Runx1, likely through the large hydrophobic patch formed upon dimerization. Since H-H dimerization was promoted by DNA binding, this Runx1 binding mechanism should enable FoxP3 to tightly coordinate DNA binding and Runx1 recruitment. Thus, a highly conserved DBD can diversify its function by gaining a multimerization capability, which may have implications beyond forkhead DBD.

Our results showed that the RBR linker was important not only for H-H dimerization but also for the forkhead DBD folding, providing an unusual example where an appendage domain altered folding of a highly conserved DBD. Given that it is a common practice to study isolated DBD for TF-DNA interactions, FoxP3 may serve as a cautionary tale for such approaches. In the absence of RBR, FoxP3 forkhead folded into the swap dimer as previously described (Bandukwala et al., 2011), whereas in the presence of RBR, it formed the canonical forkhead structure. Although the RBR-like linkers in FoxP1, 2, and 4 did not support H-H dimerization as for FoxP3, their role in stabilizing the canonical forkhead structure was conserved across the FoxP family. Our data suggest that the canonical forkhead structure is the functional form as the swap dimer did not efficiently bind DNA and Runx1. Furthermore, the IPEX mutation R337Q favored swap dimerization, compromising DNA and Runx1 binding and impairing the transcriptional activity, whereas a swap-suppressive mutation largely restored these functional impairments of R337Q. These results altogether support that canonical non-swap conformation is the physiological form of FoxP3.

The unique dependence of FoxP3 folding on RBR and its sensitivity to surface residue mutations, such as R337Q, raised the question whether FoxP3 folding landscape is complex and whether folding errors are more common than just with R337Q. In other words, swap dimerization may not just be an in vitro artifact of expressing forkhead in isolation but may readily occur in the presence of certain mutations. In keeping with this view, we found that three additional IPEX mutations near the key site that controls the domain-swap to non-swap conversion also altered the protein multimeric state, indicative of errors in protein folding. Based on these observations, we speculate that FoxP3 folding could be a novel therapeutic target; small molecules that either promote or destabilize the canonical monomeric forkhead structure or its H-H dimerization could be used to modulate Tregs in immunotherapy of cancer or autoimmunity.

**Limitations of the study**

An important limitation of this study is in identifying direct target sites in the genome using our model that FoxP3 binds DNA as a H-H dimer. Our results showed that H-H dimerization leads to an altered DNA specificity of FoxP3 compared with a monomeric
forkhead domain, but exactly which genomic sites are directly bound by Foxp3 as a result of H-H dimerization remain unclear. Future research is necessary to understand the full repertoire of DNA sequence Foxp3 recognizes and to link it to previously reported ChIP-seq or Cut&Run-seq data. Additionally, more detailed structural model of how H-H dimerization enables recruitment of Runx1 and how this recruitment affects target gene transcription need to be investigated.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - HEK293T cells
  - Naive CD4+ T cells
  - Mice
- **METHOD DETAILS**
  - Material preparation
  - Protein expression and purification
  - Electrophoretic mobility shift assay (EMSA)
  - Multi-angle light scattering (MALS)
  - Crystallization of Foxp3^AH and Foxp3^AN
  - Data collection, structure determination, and analysis
  - Co-IP of HA-Foxp3 and FLAG-Runx1
  - Co-IP of Foxp3 and DNAs
  - MBP-Foxp3^AH pulldown with DNAs
  - Biotin-DNAs pulldown with HA-Foxp3 variants
  - Biotin-DNAs pulldown with MBP-mFoxp3^AH and NFAT1 (394–680)
  - MBP-Foxp3^AH-fragment pulldown with GST-Runx1 (371–451)
  - Crosslinking analysis
  - Thermal shift assay
  - Restriction enzyme protection assay
  - CD4+ T cell cultures and retroviral transductions
  - Flow cytometry
  - Foxp3 ChIP-seq analysis
  - T cell suppression assay
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

**SUPPLEMENTAL INFORMATION**

Supplemental information can be found online at https://doi.org/10.1016/j.immuni.2022.07.002.

**ACKNOWLEDGMENTS**

We thank members of the Hur lab for discussion and critical reading of the manuscript. This study was supported by NIH grants R01AI154653 and R01AI111784 to S.H; AI150866 to C.B.; P30 CA08748 and R01 AI034206 to A.Y.R.). J.L. was supported by an INSERM Poste d’Accueil and an Arthur Sachs scholarship, and R.N.R. was supported by NIH supplement AI116834-03S1. S.H. and A.Y.R. are investigators at the Howard Hughes Medical Institute. X-ray diffraction data were collected at Advance Photon Source, beamline NECAT-24-ID-E.

**AUTHOR CONTRIBUTIONS**

F.L., W.Z., and S.H. conceived the study, designed experiments, and wrote the manuscript. F.L., W.Z., and J.L. performed experiments and analyzed data. R.N.R. and Y.Z. performed computational analysis. L.H., K.Y., and J.v.d.V. assisted experiments and analysis. A.Y.R., C.B., and S.H. supervised experimental design and data analysis.

**DECLARATION OF INTERESTS**

L.H. is co-founder of and holds equity in Edelweiss Immune Inc. A.Y.R. is an SAB member and holds equity in Sonoma Biotherapeutics, RAPT Therapeutics, Surface Oncology, Vedanta Biosciences, and an SAB member of BioInvent. S.H. is an SAB member of IFM therapeutics and CJ CheilJedang Corporation.

Received: January 24, 2022
Revised: May 3, 2022
Accepted: July 6, 2022
Published: August 1, 2022

**REFERENCES**

Arnett, K.L., Hass, M., McArthur, D.G., Ilagan, M.X., Aster, J.C., Kopan, R., and Blackburn, S.C. (2010). Structural and mechanistic insights into cooperative assembly of dimeric Notch transcription complexes. Nat. Struct. Mol. Biol. 17, 1312–1317. https://doi.org/10.1038/nsmb.1938.

Arvey, A., van der Veeken, J., Samstein, R.M., Feng, Y., Stamatoyanopoulos, J.A., and Rudensky, A.Y. (2014). Inflammation-induced repression of chromatin binding by the transcription factor Foxp3 in regulatory T cells. Nat. Immunol. 15, 580–587. https://doi.org/10.1038/ni.2868.

Badis, G., Berger, M.F., Philippakis, A.A., Talukder, S., Gehrke, A.R., Jaeger, S., Chan, E.T., Metzler, G., Venedosko, A., Chen, X., et al. (2009). Diversity and complexity in DNA recognition by transcription factors. Science 324, 1720–1723. https://doi.org/10.1126/science.1163237.

Bailey, T.L., Johnson, J., Grant, C.E., and Noble, W.S. (2015). The MEME suite. Nucleic Acids Res. 43, W39–W49. https://doi.org/10.1093/nar/gkv416.

Bandukwala, H.S., Wu, Y., Feuerer, M., Chen, Y., Barboza, B., Ghosh, S., Stroud, J.C., Benoist, C., Mathis, D., Rao, A., and Chen, L. (2011). Structure of a domain-swapped FOXP3 dimer on DNA and its function in regulatory T cells. Immunity 34, 479–491. https://doi.org/10.1016/j.immuni.2011.02.017.

Barzaghi, F., Passerini, L., and Bacchetta, R. (2012). Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immune-deficiency with autoimmune. Front. Immunol. 3, 211. https://doi.org/10.3389/fimmu.2012.00211.

Benayoun, B.A., Caburet, S., and Veitia, R.A. (2011). Forkhead transcription factors: key players in health and disease. Trends Genet. 27, 224–232. https://doi.org/10.1016/j.tig.2011.03.003.

Bennett, C.L., Christie, J., Ramsdell, F., Brunowk, M.E., Ferguson, P.J., Whitesell, L., Kelly, T.E., Saulsbury, F.T., Chance, P.F., and Ochs, H.D. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20–21. https://doi.org/10.1038/83713.

Brunowk, M.E., Jeffery, E.W., Bjornild, K.A., Paepere, B., Clark, L.B., Yasayko, S.A., Wilkinson, J.E., Galas, D., Ziegler, S.F., and Ramsdell, F. (2001). Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68–73. https://doi.org/10.1038/83784.

Chatila, T.A., Blaeser, F., Ho, N., Lederman, H.M., Voulgaropoulos, C., Helms, C., and Bowcock, A.M. (2000). JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 106, R75–R81. https://doi.org/10.1172/JCI11679.
 Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589. https://doi.org/10.1038/s41586-021-03819-2.

Kabsch, W. (2010). Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132. https://doi.org/10.1107/S0907444909067337.

Kitagawa, Y., Ohkura, N., Kidani, Y., Vandenbon, A., Hirota, K., Kawakami, R., Yasuda, K., Mutooka, D., Nakamura, S., Kondo, M., et al. (2017). Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment. Nat. Immunol. 18, 173–183. https://doi.org/10.1038/ni.3646.

Koh, K.P., Sundrud, M.S., and Rao, A. (2009). Domain requirements and sequence specificity of DNA binding for the forkhead transcription factor FOXP3. PLOS One 4, e8109. https://doi.org/10.1371/journal.pone.0008109.

Konopacki, C., Pritykin, Y., Rubtsov, Y., Leslie, C.S., and Rudensky, A.Y. (2019). Transcription factor Foxp1 regulates Foxp3 chromatin binding and coordinates regulatory T cell function. Nat. Immunol. 20, 232–242. https://doi.org/10.1038/s41590-018-0291-z.

Kwon, H.-K., Chen, H.-M., Mathis, D., and Benoist, C. (2017). Different molecular complexes that mediate transcriptional induction and repression by FoxP3. Nat. Immunol. 18, 1238–1248. https://doi.org/10.1038/nri.3835.

Kwon, H.K., Chen, H.M., Mathis, D., and Benoist, C. (2018). FoxP3 scanning mutagenesis reveals functional variation and mild mutations with atypical autoimmune phenotypes. Proc. Natl. Acad. Sci. USA 115, E253–E262. https://doi.org/10.1073/pnas.1718599115.

Lambert, S.A., Jolma, A., Campitielli, L.F., Das, P.K., Yin, Y., Albu, M., Chen, X., Taipale, J., Hughes, T.R., and Weirauch, M.T. (2018). The human transcription factor FOXP3. Cell 172, 650–665. https://doi.org/10.1016/j.cell.2018.01.029.

Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359. https://doi.org/10.1038/nmeth.1923.

Li, B., Samanta, A., Song, X., Iacono, K.T., Bembas, K., Tao, R., Basu, S., Riley, J.L., Hancock, W.W., Shen, Y., et al. (2007). FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl. Acad. Sci. USA 104, 4571–4576. https://doi.org/10.1073/pnas.0702991104.

Liebschner, D., Afonine, P.V., Baker, M.L., Bunkóczi, G., Chen, V.B., Croll, T.J., Hintze, B., Hung, L.W., Jain, S., McCoy, A.J., et al. (2019). Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861–877. https://doi.org/10.1107/S2053229618002146.

Lozano, T., Gorraiz, M., Lasarte-Cia, A., Ruiz, M., Rabal, O., Oyarzabal, J., Hervás-Stubbis, S., Llopiz, D., Sarobe, P., Prieto, J., et al. (2017). Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. Oncotarget 8, 7109–71214. https://doi.org/10.18632/oncotarget.17845.

McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674. https://doi.org/10.1107/S0021889807021205.

Mushudov, G.N., Skubák, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., Winn, M.D., Long, F., and Vagin, A.A. (2011). REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367. https://doi.org/10.1107/S0907444910001314.

Nakagawa, S., Gisselbrecht, S.S., Rogers, J.M., Hartl, D.L., and Bulyk, M.L. (2013). DNA-binding specificity changes in the evolution of forkhead transcription factors. Proc. Natl. Acad. Sci. USA 110, 12349–12354. https://doi.org/10.1073/pnas.1303031104.

Newman, J.A., Atkenhead, H., Gavard, A.E., Rota, I.A., Handel, A.E., Hollander, G.A., and Gileadi, O. (2020). The crystal structure of human forkhead box N1 in complex with DNA reveals the structural basis for forkhead box family specificity. J. Biol. Chem. 295, 2948–2958. https://doi.org/10.1074/jbc.RA119.010365.

Nitta, K.R., Jolma, A., Yin, Y., Morgunova, E., Kivioja, T., Akhtar, J., Hens, K., Toivonen, J., Deplancke, B., Furlong, E.E., et al. (2015). Conservation of transcription factor binding specificities across 600 million years of Bilateria evolution. eLife 4, e04837. https://doi.org/10.7554/eLife.04837.

Ono, M., Yaguchi, H., Ohkura, N., Klibayashi, I., Nagamura, Y., Nomura, T., Miyachi, Y., Tsukada, T., and Sakaguchi, S. (2007). Foxp3 controls regulatory
T-cell function by interacting with AML1/Runx1. Nature 446, 685–689. https://doi.org/10.1038/nature05673.

Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326.

Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and Ferrin, T.E. (2004). UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612.

Pfeifer, K., Prezant, T., and Guarente, L. (1987). Yeast HAP1 activator binds to two upstream activation sites of different sequence. Cell 49, 19–27. https://doi.org/10.1016/0092-8674(87)90751-9.

Pricer, R., Gestwicki, J.E., and Mapp, A.K. (2017). From fuzzy to function: the new frontier of protein-protein interactions. Acc. Chem. Res. 50, 584–589. https://doi.org/10.1021/acs.accounts.6b00565.

Ramirez, R.N., Chowdhary, K., Leon, J., Mathis, D., and Benoist, C. (2022). Foxp3 associates with enhancer-promoter loops to regulate Treg-specific gene expression. Sci. Immunol. 7, eabj8836.

Reiter, F., Wienerroither, S., and Stark, A. (2017). Combinatorial function of transcription factors and cofactors. Curr. Opin. Genet. Dev. 43, 73–81. https://doi.org/10.1016/j.gde.2016.12.007.

Rogers, J.M., Waters, C.T., Seegar, T.C.M., Jarrett, S.M., Hallworth, A.N., Blacklow, S.C., and Bulyk, M.L. (2019). Bispecific forkhead transcription factor FoxN3 recognizes two distinct motifs with different DNA shapes. Mol. Cell 74, 245–254.e6. https://doi.org/10.1016/j.molcel.2019.01.019.

Rubio-Cabezas, O., Minton, J.A., Caswell, R., Shield, J.P., Deiss, D., Sumnik, Z., Cayssials, A., Herr, M., Loew, A., Lewis, V., et al. (2009). Clinical heterogeneity in patients with FOXP3 mutations presenting with neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nature 459, 971–984.e5. https://doi.org/10.1038/nature08144.

Rudra, D., deRoos, P., Chaudhry, A., Niec, R.E., Arvey, A., Samstein, R.M., Leslie, C., Shaffer, S.A., Goodlett, D.R., and Rudensky, A.Y. (2012). Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat. Immunol. 13, 1010–1019. https://doi.org/10.1038/ni.2402.

Samstein, R.M., Arvey, A., Josefowicz, S.Z., Peng, X., Reynolds, A., Sandstrom, R., Nephe, S., Sabo, P., Kim, J.M., Liao, W., et al. (2012). Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. Cell 151, 153–166. https://doi.org/10.1016/j.cell.2012.06.055.

Sefik, E., Geva-Zatorsky, N., Oh, S., Konnikova, L., Zemmour, D., Mcguire, A.M., Burzin, D., Ortiz-Lopez, A., Lobera, M., Yang, J., et al. (2015). Mucosal immunology. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science 349, 993–997. https://doi.org/10.1126/science.aaa4920.

Segal, E., Raveh-Sadka, T., Schroeder, M., Unnerstall, U., and Gafi, U. (2008). Predicting expression patterns from regulatory sequence in Drosophila segmentation. Nature 451, 535–540. https://doi.org/10.1038/nature06496.

Song, X., Li, B., Xiao, Y., Chen, C., Wang, Q., Liu, Y., Berezov, A., Xu, C., Gao, Y., Li, Z., et al. (2012). Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function. Cell Rep. 1, 665–675. https://doi.org/10.1016/j.celrep.2012.04.012.

Stroud, J.C., Wu, Y., Bates, D.L., Han, A., Nowick, K., Paabo, S., Tong, H., and Chen, L. (2006). Structure of the forkhead domain of FOXP2 bound to DNA. Structure 14, 159–166. https://doi.org/10.1016/j.str.2005.10.005.

Tanaka, H., Tsugawa, K., Kudo, M., Sugimoto, K., Kobayashi, I., and Ito, E. (2005). Low-dose cyclosporine A in a patient with X-linked immune dysregulation, polyendocrinopathy and enteropathy. Eur. J. Pediatr. 164, 779–780. https://doi.org/10.1007/s00431-005-1746-4.

Terwilliger, T.C., Grosske-Kunstleve, R.W., Alonine, P.V., Moriarty, N.W., Zwart, P.H., Hung. L.W., Read, R.J., and Adams, P.D. (2008). Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr. D Biol. Crystallogr. 64, 61–69. https://doi.org/10.1107/S090744490705024X.

Tuttle, L.M., Pacheco, D., Warfield, L., Wilburn, D.B., Hahn, S., and Klevit, R.E. (2021). Mediator subunit Med15 dictates the conserved ‘fuzzy’ binding mechanism of yeast transcription activators Gal4 and Gcn4. Nat. Commun. 12, 2220. https://doi.org/10.1038/s41467-021-22441-4.

van der Veeken, J., Gisner, A., Zhong, Y., Hu, W., Wang, Z.M., Bou-Pru, R., Charbonnier, L.M., Chatila, T.A., Leslie, C.S., and Rudensky, A.Y. (2020). The transcription factor Foxp3 shapes regulatory T cell identity by tuning the activity of trans-acting intermediaries. Immunity 53, 971–984.e5. https://doi.org/10.1016/j.immuni.2020.01.010.

Van Goor, F., Nguyen, M.L.T., Mumbach, M.R., Satpathy, A.T., Rosenthal, W.L., Giacometti, S., Le, D.T., Liu, W., Brusko, T.M., Anderson, M.S., et al. (2019). A mutation in the transcription factor Foxp3 drives T helper 2 effector function in regulatory T cells. Immunity 50, 362–377.e6. https://doi.org/10.1016/j.immuni.2018.12.016.

Wildin, R.S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J.L., Buist, N., Levy-Lahad, E., Mazzella, M., Goulet, O., Perroni, L., et al. (2001). X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27, 18–20. https://doi.org/10.1038/83707.

Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G.W., McCoy, A., et al. (2011). Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol. Crystallogr 67, 235–242.

Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A.D., Stroud, J.C., Bates, D.L., Guo, L., Han, A., Ziegler, S.F., et al. (2006). FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375–387. https://doi.org/10.1016/j.cell.2006.05.042.

Yoshida, H., Lareau, C.A., Ramirez, R.N., Rose, S.A., Maier, B., Wroblewska, A., Deslandes, F., Chudnovskiy, A., Mortha, A., Dominguez, C., et al. (2019). The cis-regulatory atlas of the mouse immune system. Cell 176, 897–912.e20. https://doi.org/10.1016/j.cell.2018.12.036.

Zemmour, D., Charbonnier, L.M., Leon, J., Six, E., Keles, S., Delville, M., Benamar, M., Baris, S., Zuber, J., Chen, K., et al. (2021). Single-cell analysis of FOXP3 deficiencies in humans and mice unmask intrinsically and extrinsically regulated T cell perturbations. Nat. Immunol. 22, 607–619. https://doi.org/10.1038/s41590-021-00910-8.

Zemmour, D., Pratama, A., Loughhead, S.M., Mathis, D., and Benoist, C. (2017). FlcR, a long noncoding RNA, modulates Foxp3 expression and autoimmunity. Proc. Natl. Acad. Sci. USA 114, E3472–E3480. https://doi.org/10.1073/pnas.1700946114.

Zheng, Y., Josefowicz, S.Z., Kas, A., Chu, T.T., Gavrin, M.A., and Rudensky, A.Y. (2007). Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445, 936–940. https://doi.org/10.1038/nature05663.
## STAR*METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**       |        |            |
| Anti-rabbit IgG-HRP  | Cell Signaling Technology | Cat# 7074 |
| Rabbit anti-beta-actin | Cell Signaling Technology | Cat# 8457S |
| Rabbit anti-HA C29F4 | Cell Signaling Technology | Cat# 3724S |
| Mouse Anti-FLAG-HRP  | Sigma-Aldrich | Cat# A8592 |
| Mouse MBP Tag antibody(8G1) | Cell Signaling Technology | Cat# 2396 |
| GST-Tag Antibody     | Cell Signaling Technology | Cat# 2622 |
| PE anti-mouse CD4 Antibody | Biolegend | Cat# 100408 |
| APC/Cyanine7 anti-rat CD90/mouse CD90.1 (Thy-1.1) Antibody | Biolegend | Cat# 202520 |
| FoxP3 Monoclonal Antibody (FJK-16s), Alexa Fluor 700 | eBioscience | Cat# 56-5773-82 |
| Brilliant Violet 421™ anti-mouse CD152 Antibody | Biolegend | Cat# 106311 |
| Pacific Blue™ anti-mouse CD25 Antibody | Biolegend | Cat# 102022 |
| PE/Cyanine7 anti-mouse/human CD44 Antibody | Biolegend | Cat# 103029 |
| APC anti-mouse CD62L Antibody | Biolegend | Cat# 104411 |
| Ultra-LEAF™ Purified anti-mouse CD3e Antibody | Biolegend | Cat# 100340 |
| Ultra-LEAF™ Purified anti-mouse CD28 Antibody | Biolegend | Cat# 102116 |
| eBioscience™ Fixable Viability Dye eFluor™ 506 | Invitrogen | Cat# 65-0866-14 |
| Anti-mouse CD45 (30-F11) | BioLegend | Cat# 103101 |
| Anti-mouse CD4 (RM4-5) | BioLegend | Cat# 100505 |
| Anti-mouse CD25 (PC61) | BioLegend | Cat# 102007 |
| Anti-mouse TCRb (H57–597) | BioLegend | Cat# 109201 |
| Anti-mouse CD44 (IM7) | BioLegend | Cat# 103007 |
| Anti-mouse FoxP3 (clone FJK-16s) | Invitrogen | Cat# 14-5773-82 |
| Anti-mouse CTLA4/CD152 (clone UC10-4B9) | BioLegend | Cat# 106302 |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| Ni-NTA agarose      | QIAGEN | Cat# 30250 |
| HRV 3C protease     | Homemade | N/A |
| HiTrap Heparin      | GE Healthcare | Cat# 17040601 |
| Superdex 200 Increase 10/300 | GE Healthcare | Cat# 28990944 |
| Superdex 75 Increase 10/300 | GE Healthcare | Cat# 29148721 |
| HiTrap SP           | GE Healthcare | Cat# 17505301 |
| Benzonase           | Millipore | Cat# 70746-3 |
| Amylose Resin       | New England Biolabs | Cat# E8021 |
| Mammalian protease arrest | GBiosciences | Cat# 786-433 |
| Proteinase K        | New England Biolabs | Cat# P6107S |
| Lipofectamine 3000  | Invitrogen | Cat# L3000008 |
| SYBR Gold stain     | Invitrogen | Cat# S11494 |

(Continued on next page)
Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| DMEM, high glucose, pyruvate | Cellgro | Cat# 10-013-CV |
| Phusion polymerase | New England Biolabs | Cat# M0530L |
| XhoI | New England Biolabs | Cat# R1046 |
| BamHI-HF | New England Biolabs | Cat# R3136 |
| EcoRI-HF | New England Biolabs | Cat# R3101 |
| Krypton Fluorescent Protein Stain | Thermo Scientific | Cat# 46630 |
| Bismaleimidoethane (BMOE) | Thermo Scientific | Cat# 22323 |
| Deoxyribonuclease | Sigma | Cat# DN25 |
| Novex TBE Gels, 20% | Invitrogen | Cat# EC63155BOX |
| Novex TBE Gels, 10% | Invitrogen | Cat# EC62755BOX |
| Mini-PROTEAN TGX Precast Protein Gels, 4-15% | BioRad | Cat# 4561086 |
| Bis-Tris native PAGE, 3-12% | Invitrogen | Cat# BN1003BOX |
| Anti-HA Magnetic Beads | Thermo Scientific | Cat# 88837 |
| Pierce<sup>TM</sup> High Capacity Streptavidin Agarose | Thermo Fisher | Cat# 20359 |
| TriDye<sup>TM</sup> Ultra Low Range DNA Ladder | New England Biolabs | Cat# N0558S |
| Normal Mouse Serum | Thermo Fisher | Cat# 10410 |
| Recombinant Human IL-2 | Peprotech | Cat# 200-02 |

Critical commercial assays

| ASSAY | SOURCE | IDENTIFIER |
|-------|--------|------------|
| Thermol shift assay kit | Thermo Fisher | Cat# 4461146 |
| QIAquick Nucleotide Removal kit | QIAGEN | Cat# 28304 |
| Dynabeads<sup>TM</sup> Mouse T-Activator CD3/CD28 for T-Cell Expansion and Activation | Thermofisher | Cat# 11452D |
| Naive CD4<sup>+</sup> T Cell Isolation Kit, mouse | Miltenyi Biotec | Cat# 130-104-453 |
| FoxP3<sup>+</sup> / Transcription Factor Staining Buffer Set | eBioscience<sup>TM</sup> | Cat# 00-5523-00 |
| CD3<sup>ε</sup> MicroBead Kit, mouse | Miltenyi Biotec | Cat# 130-094-973 |
| CellTrace<sup>TM</sup> CFSE Cell Proliferation Kit, for flow cytometry | Invitrogen | Cat# C34554 |

Deposited data

| DEPOSITED DATA | SOURCE |
|----------------|--------|
| FoxP3<sup>DN</sup>' coordinates and map | This study |
| FoxP3<sup>DN</sup> coordinates and map | This study |

Experimental models: Cell lines

| EXPERIMENTAL MODELS: CELL LINES | SOURCE |
|-------------------------------|--------|
| HEK293T cells | This study |
| CD4<sup>+</sup> T cells | This study |

Experimental models: Organisms/strains

| EXPERIMENTAL MODELS: ORGANISMS/STRAINS | SOURCE |
|----------------------------------------|--------|
| E. coli BL21 (DE3) | Stratagene |
| B6 mice | This study |
| B6, FoxP3<sup>R332Q/DN</sup> mice | This study |

Oligonucleotides

| OLIGONUCLEOTIDES | SOURCE |
|------------------|--------|
| DNAs | See Table S2 |
| Biotin-DNAs | See Table S2 |

Recombinant DNA

| RECOMBINANT DNA | SOURCE |
|-----------------|--------|
| pET50b-FoxP3<sup>DN</sup> | This study |
| pET50b-FoxP3<sup>DN</sup>-L241D | This study |
| pET50b-FoxP3<sup>DN</sup>-K215A | This study |
| pET50b-FoxP3<sup>DN</sup> | This study |
| pET50b-FoxP3<sup>DN</sup> | This study |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| pET50b-FoxP3ZF-CC   | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -A372P | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -A372G | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -A372S | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -R337Q | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -R337Q+R372S | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -Y373V | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -F331D | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -I346T | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -R347H | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -F367L | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -I363V | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -F367L | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -M370I | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -F371C | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -F371A | This study | N/A        |
| pET50b-FoxP3 RBR-forkhead -F371C | This study | N/A        |
| pcDNA3.1+            | This study | N/A        |
| pcDNA-HA-FoxP3       | This study | N/A        |
| pcDNA-HA-FoxP3-F325D | This study | N/A        |
| pcDNA-HA-FoxP3-K332D | This study | N/A        |
| pcDNA-HA-FoxP3-R347H | This study | N/A        |
| pcDNA-HA-FoxP3-W348D | This study | N/A        |
| pcDNA-HA-FoxP3-R348D | This study | N/A        |
| pcDNA-HA-FoxP3-R348D | This study | N/A        |
| pcDNA-HA-FoxP3-R348D | This study | N/A        |
| (Continued on next page) | | |
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Sun Hur (sun.hur@crystal.harvard.edu).

Materials availability
All plasmids generated in this study are available from the lead contact with a completed Materials Transfer Agreement.

Data and code availability
The atomic coordinates have been deposited in the Protein Data Bank with accession codes: 7TDW and 7TDX.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

HEK293T cells
Cells were maintained in DMEM (High glucose, L-glutamine, Pyruvate) with 10% fetal bovine serum, 1% penicillin/streptomycin.
**Naive CD4+ T cells**

Cells were isolated by using Naive CD4+ T Cell Isolation Kit (Miltenyi Biotec, Cat#130-104-453) according to the manufacturer’s instructions and maintained in complete RPMI medium (10% FBS heat-inactivated, 2mM L-Glutamine, 1mM Sodium Pyruvate, 100μM NEAA, 5mM HEPES, 0.05mM 2-ME).

**Mice**

B6.Foxp3R337Q/Doi mice were generated by CRISPR mutagenesis as described (Zemmour et al., 2017). Except that, instead of Cas9-encoding mRNA, a nucleoprotein complex (0.13μM Alt-R® S.p. HiFi Caspase 9 (IDT), 0.6μM sgRNA, and 0.3μM of a single-stranded recombination template carrying the desired mutation with ~60 bp of flanking homology arms, mixed in 0.2μM filtered 0.1X TE Buffer) was microinjected into the male pronucleus of fertilized mouse oocytes, then implanted into pseudo-pregnant females. The resulting mutation (GA>AG at position 1286-1287 in exon 11, NM_054039.2) encodes the R337Q missense mutation, at the very beginning of the FKHR domain. The presence of the mutation and absence of other changes in the Foxp3 coding sequence were verified by Sanger sequencing. The germline mutation was maintained by crossing onto the B6 background, and routinely carried with heterozygous female breeders. For the experiments reported here, 8-week-old R337Q males and their WT B6 littermates were analyzed. Data from two independent litters were pooled. All experiments were performed following animal protocols approved by the HMS Institutional Animal Use and Care Committee (protocols IS00000054).

**METHOD DETAILS**

**Material preparation**

**Plasmids**

Mouse Foxp3 was used for all analyses. For bacterial expression of Foxp3 variants, the genes encoding mouse Foxp3\(^{ΔN}\) (residues 188-423), Foxp3\(^{RBR	ext{-forkhead}}\) (residues 284-423), Foxp3\(^{forkhead}\) (residues 336-423), Foxp3\(^{2\text{F-CC}}\) (residues 188-284) were inserted into pET50b between Xmal and HindIII sites, and into a modified pMAL-c2 vector between BamHI and XbaI sites respectively. All mutations within Foxp3 were generated by site-directed mutagenesis using Phusion High Fidelity (New England Biolabs) DNA polymerases. For crystallization, the gene encoding mouse Foxp3\(^{ΔN}\) (residues 204-276+305-417) and Foxp3\(^{ΔN′}\) (residues 204-276+315-417) were cloned into pET50b using overlap extension PCR. Mouse Foxp1\(^{RBR	ext{-forkhead}}\) (residues 433-579), mouse Foxp2\(^{ΔN}\) (residues 353-588), mouse Foxp2\(^{RBR	ext{-forkhead}}\) (residues 447-588) and mouse Foxp4\(^{RBR	ext{-forkhead}}\) (residues 418-577) were cloned into pET50b between Xmal and HindIII sites, and modified pMAL-c2 vector between BamHI and XbaI sites respectively. Mouse Runx1 (residues 371-451) was cloned into pGEX-6P-1 between EcoRI and Xhol. Mouse NFAT1 (residues 394-680) was cloned into pET50b plasmid between Xmal and HindIII sites.

For Mammalian expression plasmids, HA-tagged mouse Foxp3 CDS was inserted into pcDNA3.1+ vector between KpnI and BamHI sites. All Foxp3 mutations including F325D, F331D, H334D, R337Q, R347H, W348D and R337Q/A372S were generated by site-directed mutagenesis using Phusion High Fidelity (New England Biolabs) DNA polymerases. The genes encoding mouse Runx1 and NFAT1 were inserted into pFlag-CMV4 vector between EcoRI and Xhol, and between NotI/XbaI sites respectively. For retroviral packaging plasmids, HA-tagged mouse FOXP3 CDS was inserted into MSCV-IRES-Thy1.1 vector. All Foxp3 mutations including F325D, F331D, K332D, H334D, R337Q, R347H, W348D, A372S, A372G, R337Q/A372S and Y373V were generated by site-directed mutagenesis using Phusion High Fidelity (New England Biolabs) DNA polymerases.

**DNAs**

Single-stranded DNA oligos were synthesized by IDTDNA. Double-stranded DNAs for EMSA assay, pulldown assay and restriction enzyme protection assay were annealed from single-stranded, complementary oligos. After briefly spinning down each oligonucleotide pellet, ssDNAs were dissolved in annealing buffer (10 mM Tris pH 7.5, 50 mM NaCl). Complementary ssDNAs were then mixed together in equal molar amounts, heated to 94°C for 2 minutes and gradually cool down to room temperature. For dsDNAs used in crystallization, HPLC purified single-stranded, complementary oligos were purchased from IDTDNA. After annealing, dsDNA was further purified by size-exclusion chromatography on Superdex 75 Increase 10/300 (GE Healthcare) columns in 20 mM Tris pH 7.5, 150 mM NaCl. Biotin labeled ssDNA were synthesized by IDTDNA and then dissolved in annealing buffer (10 mM Tris pH 7.5, 50 mM NaCl). Complementary biotin labeled ssDNAs were then mixed together in equal molar amounts, heated to 94°C for 2 minutes and gradually cool down to room temperature.

**Protein expression and purification**

All recombinant proteins in this paper were expressed in BL21(DE3) at 18°C for 16-20 hr following induction with 0.2 mM IPTG. Cells were lysed by high-pressure homogenization using an Emulsiflex C3 (Avestin). All proteins are from the Mus. musculus sequence. Foxp3\(^{ΔN}\), Foxp3\(^{ΔN′}\) and Foxp3\(^{ΔN″}\) were expressed as a fusion protein with N-terminal His\(_{6}\)-NusA tag. After purification using Ni-NTA agarose, the proteins were treated with HRV3C protease to cleave the His\(_{6}\)-NusA-tag and were further purified by a combination of chromatography using HiTrap Heparin (GE Healthcare) and Hitrip SP (GE Healthcare), followed by Superdex 200 Increase 10/300 (GE Healthcare) columns in 20 mM Tris-HCl pH 7.5, 500 mM NaCl, 2 mM DTT. Foxp3\(^{RBR	ext{-forkhead}}\), Foxp3\(^{forkhead}\) and NFAT1 (residues 394-680) were expressed as fusion protein with N-terminal His\(_{6}\)-NusA tag. After purification using Ni-NTA agarose, the proteins were treated with HRV3C protease to cleave the His\(_{6}\)-NusA-tag and were further purified by size-exclusion chromatography on Superdex 75 Increase 10/300 (GE Healthcare) column in 20 mM Tris-HCl pH 7.5, 500 mM NaCl, 5% Glycerol, 2 mM DTT. His\(_{6}\)-MBP fused...
Crystallization of FoxP3 was tried with various constructs and DNA, but crystals were only obtained with FoxP3 

\[
\text{FoxP3}^{AN}, \text{FoxP3}^{RBR-\text{forkhead}}, \text{FoxP2}^{AN} \text{and His}_{2}-\text{GST fused Runx1} \text{ (residues 371-451) were purified by a combination of chromatography on Ni-NTA agarose and Superdex 200 Increase 10/300 (GE Healthcare) columns in 20 mM Tris-Hcl pH 7.5, 500 mM NaCl, 2 mM DTT. For SEC-MALS analysis, proteins were purified without HRV3C cleavage to increase the molecular weight of the protein for accurate size determination. His}_{2}-\text{NusA fused FoxP3 variants, FoxP1}^{RBR-\text{forkhead}}, \text{FoxP2}^{RBR-\text{forkhead}} \text{and FoxP4}^{RBR-\text{forkhead}} \text{were purified by Ni-NTA agarose affinity chromatography, followed by size-exclusion chromatography on Superdex 200 Increase 10/300 (GE Healthcare) columns in 20 mM Tris-Hcl pH 7.5, 500 mM NaCl, 2 mM DTT.}
\]

**Electrophoretic mobility shift assay (EMSA)**

0.2 μM of DNA was mixed with the indicated amount of FoxP3 variants or other FoxP proteins in the buffer (20 mM Tris-Hcl pH 7.5, 150 mM NaCl, 1.5 mM MgCl₂, and 2 mM DTT). Proteins and DNAs were incubated for 30 min at 4 °C and analyzed on 3-12% gradient Bis-Tris native gels (Life Technologies) at 4 °C. After staining with Sybr Gold stain (Life Technologies), Sybr Gold fluorescence was recorded using iBright FL1000 (Invitrogen) and analyzed with iBright Analysis Software.

**Multi-angle light scattering (MALS)**

NusA-fused FoxP3 variants, FoxP1^{RBR-\text{forkhead}}, FoxP2^{RBR-\text{forkhead}} and FoxP4^{RBR-\text{forkhead}} were analyzed with Superdex 200 Increase 10/300 column (GE Healthcare), which was connected to a miniDAWN MALS detector (Wyatt Technology) and an Optilab differential refractive index (dRI) detector (Wyatt Technology). The buffer (20 mM Tris-Hcl pH 7.5, 150 mM Nacl, 2 mM DTT) was used for size-exclusion chromatography. The AKTA pure (GE Healthcare)’s UV 280 nm absorbance signal was used for concentration detection. The Optilab differential refractive index (dRI) detector measured dRI data for additional concentration analysis. Data analysis and MW calculations were performed using the ASTRA7.3.1 software (Wyatt Technology).

**Crystallization of FoxP3^{AN} and FoxP3^{3N}**

Crystallization of FoxP3 was tried with various constructs and DNA, but crystals were only obtained with FoxP3^{AN} and FoxP3^{3N}, which had C217S and C231S mutations and internal deletions in the RBR loop. FoxP3^{AN} contained residues 204-276 and 305-417, while FoxP3^{3N} contained residues 204-276 and 315-417. Purified proteins (post Superdex 200 Increase) were mixed with purified IR-FKHMM4g dsDNA (5’-AAATTTGTTTAC

\[
\text{TCGAGTAAACA}
\]

and post Superdex 75 Increase 10/300) at 1:1.2 molar ratio in 20 mM Tris-Hcl pH 7.5, 150 mM Nacl, 3 mM 2-mercaptoethanol and the mixture was concentrated to 10 mg/ml (Protein concentration) using an Amicon Ultra-4 filter (3 kDa molecular-weight cutoff, Millipore). The FoxP3^{3N}-DNA complex was then mixed with the reservoir solution (0.1 M Tris-Hcl pH 8.5, 12% PEG4000) at a 1:1 volume ratio and was crystallized at 18 °C by vapor diffusion using the hanging drop method. Crystals for the FoxP3^{3N}-DNA complex grew in the reservoir solution (0.5 M Lithium sulfate, 2% PEG8000) and were obtained using a similar method as with FoxP3^{AN}. To test whether the FoxP3^{AN} protein was intact in the crystal, a single crystal was picked, washed three times in 10 μl reservoir solution and then directly transferred into 10 μl of 1x SDS sample buffer prior to SDS-PAGE analysis. The protein was visualized by Krypton stain (Thermo Scientific).

**Data collection, structure determination, and analysis**

Crystals were cryoprotected in the reservoir solution supplemented with 25% glycerol and were flash-cooled in liquid nitrogen. The X-ray diffraction data were collected at the Advance Photon Source, beamline NECAT-24-ID-E. Diffraction data were processed using XDS (Kabsch, 2010) and HKL2000 (Otwinowski and Minor, 1997) in P6₃222 symmetry. The FoxP3^{3N}-DNA complex structure was solved by molecular replacement with Phaser (McCoy et al., 2007) using canonical forkhead structures of FoxN1 (PDB 6EL8) and ~14 bp DNA molecule (from PDB: 3QRF). The known structure of FoxP3 forkhead domain (PDB: 3QRF) and FoxP3 coiled-coil domain (PDB: 411L) were also tried as molecular replacement templates, but no solution was obtained. The MR solution for DNA showed that two 14 bp DNAs face each other through 2-fold symmetry in a way that can make one continuous 28 bp DNA, which was the biological sample used for crystallization. The data processed with P6₃ symmetry showed a single FoxP3 dimer bound to 28 bp DNA in the asymmetric unit, of which the structure was nearly identical to that obtained with P6₃222. However, data merging statistics and quality of the electron density map were inferior to those obtained with P6₃222. Therefore, P6₃222 was used for subsequent model building and refinement. The model of FoxP3^{AN} monomer with 14bp DNA was automatically built using Autobuild (Terwilliger et al., 2008), followed by manual model building using COOT (Emsley et al., 2010). Structural refinement was performed with PHENIX (Liebeschner et al., 2019) and REFMAC5 in ccP4 (Murshudov et al., 2011). The FoxP3^{3N}-DNA complex structure was solved by molecular replacement using the model of the FoxP3^{3N}-DNA complex, followed by structural refinement using PHENIX and REFMAC5. The atomic coordinates of FoxP3^{AN}-DNA and FoxP3^{3N}-DNA have been deposited in the Protein Data Bank with accession codes 7TDW and 7TDX, respectively. Data collection and refinement statistics are summarized in Table S1. Figures of structure illustration were prepared using Pymol (Schrödinger, LLC).

**Co-IP of HA-FoxP3 and FLAG-Runx1**

HEK293T cells (in 6-well plate) were transfected with empty vector or pcDNA encoding HA-tagged FoxP3 (wild-type or mutants), or pFlag-Runx1-CMV4 respectively using Lipofectamine 3000 (Life Technologies) following manufacturer’s instructions. 48 hours later, cells were washed twice in 1XPBS (1 ml of PBS for each well) and spun down at 500g for 5 mins. Cells were resuspended in 500 μl lysis buffer (20 mM HEPES pH 7.5, 0.05% IGEPAL, 1.5 mM MgCl₂, 10 mM KCl, 5 mM EDTA and 1x Mammalian protease cocktail) for 15 minutes at 4 °C and were spun down at 500g for 5 minutes at 4 °C. The supernatant was collected and centrifuged at 14000 rpm for
another 5 minutes. Soluble fractions containing HA-FoxP3 and Flag-Runx1 (400 µl each) were mixed together and incubated with anti-HA magnetic beads (4 µl) (Thermo Scientific) for 1 hour at 4°C with slow rotation. To examine if FoxP3–Runx1 interaction was dependent on nucleic acids, 4 µl or 8 µl of Benzonase (Millipore) was added to the FoxP3 and Runx1 mixture for 10 minutes at 25°C. Beads were washed three times with RIPA buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1% Triton X-100, 50 mM NaCl, 0.5% Sodium Deoxycholate, 0.1% SDS, 150 mM NaCl, 1x Mammalian protease cocktail), followed by protein elution using SDS loading buffer and analysis by SDS-PAGE.

**Co-IP of FoxP3 and DNAs**

HEK293T cells were transfected with pcDNA encoding HA-tagged FoxP3 (wild-type or mutants). After 48 hours, cells were lysed using RIPA buffer (10mM Tris-HCl, pH 8.0, 1mM EDTA, 1% Triton X-100, 0.1% Sodium Deoxycholate, 0.1% SDS, 140 mM NaCl and 1x proteinase inhibitor) and treated with Benzonase (Millipore) for 30 mins. The lysate was then incubated with Anti-HA Magnetic Beads (Thermo Fisher) for 1 hour. Beads were washed three times using RIPA buffer and incubated with DNA oligos for 20 mins at room temperature. Bound DNA was recovered using proteinase K (New England Biolabs), purified using QIAquick Nucleotide Removal kit (Qiagen) and analyzed on 10% Novex TBE Gels (Invitrogen).

**MBP-FoxP3*3N pulldown with DNAs**

Purified MBP-mFoxP3*3N or MBP-FoxP2*3N protein (0.4 µM) was incubated with DNA (0.1 µM) in the buffer (20 mM Tris, pH 7.5, 100 mM NaCl, 1.5 mM MgCl2) for 20 mins at RT, and was further incubated with Amylose Resin (25 µl) (New England Biolabs) with rotation for 30 mins at RT. Bound DNA was recovered using proteinase K (New England Biolabs), purified using QIAquick Nucleotide Removal kit (Qiagen) and analyzed on 10% Novex TBE Gels (Invitrogen).

**Biotin-DNAs pulldown with HA-FoxP3 variants**

HEK293T cells were transfected with pcDNA-HA-FoxP3 (wild-type or mutations) and lysed using RIPA buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% Sodium Deoxycholate, 0.1% SDS, 140 mM NaCl and 1x proteinase inhibitor). Biotin-dsDNA (1 µM) was incubated with the lysate for 1 hour. Streptavidin Agarose (25 µl (Thermo Fisher) was added and further incubated for 30 mins with rotation. Beads were washed three times using RIPA buffer and eluted using SDS loading buffer prior to SDS-PAGE analysis.

**Biotin-DNAs pulldown with MBP-mFoxP3*3N and NFAT1 (394-680)**

Purified MBP-FoxP3*3N protein (0.2 µM) was incubated with purified NFAT1 (394-680) protein (0.008, 0.04, 0.2 µM) and Biotin-DNAs (0.2 µM) for 10 mins at room temperature in 20 mM Tris-HCl, pH 7.5, 100M Nacl, 2mM Mgcl2, 0.1% NP40, 2mM DTT. Streptavidin Agarose beads (25 µL) (Thermo Fisher) were added and incubated with rotation for 10 mins at 4°C. Beads were washed three times with incubation buffer, prior to elution and analysis by SDS-PAGE or TBE gels.

**MBP-FoxP3*RBR-forkhead pulldown with GST-Runx1(371-451)**

Purified MBP-FoxP3*RBR-forkhead protein (1 µM) was incubated with purified GST-Runx1(371-451) protein (0.5 µM) with or without 2 µM DNA for 30 mins at room temperature in RIPA buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1% Triton X-100, 50 mM NaCl, 0.5% Sodium Deoxycholate, 0.1% SDS, 140 mM NaCl and 1x proteinase inhibitor). Streptavidin Agarose beads (25 µL) (Thermo Fisher) were added and incubated with rotation for 30 mins at RT. Beads were washed three times with RIPA buffer, prior to elution and analysis by SDS-PAGE or TBE gels.

**Crosslinking analysis**

Protein-protein crosslinking using BMOE (Thermo Scientific) was carried out according to the product manual. Briefly, BMOE was added to 2 µM of FoxP3*forkhead protein to a final concentration of 100 µM in 1XPBS. After 1-hour incubation at 25°C, DTT (10 mM) was added to quench the crosslinking reaction. Samples were then analyzed by SDS-PAGE and Krypton staining (Thermo Scientific).

**Thermal shift assay**

WT FoxP3*RBR-forkhead and mutations (19 µl, 0.25 mg/ml) were mixed with 20x Protein thermal shift dye (1 µl) (Thermo Scientific) in SEC buffer (50 mM Tris-HCl pH 7.5, 150 mM Nacl, 2 mM DTT) and aliquoted into MicroAmp Optical 96-Well Reaction Plate (Applied Biosystems). Thermal shift assay was performed using StepOnePlus Real-Time PCR System (Applied Biosystems). Briefly, temperature was increased in a step-and-hold manner from 25°C to 98°C in a 0.3°C/cycle increment and with an equilibration time of 15s at each temperature. Normalized reporter (Rn) view visualizing the rise in fluorescence throughout the temperature ramp were generated by onestep plus software. The normalized reporter (Rn), displayed on the y-axis, is calculated as the fluorescence signal from the reporter dye normalized to the fluorescence signal of the passive reference.

**Restriction enzyme protection assay**

IR-FKH*1g and IR-FKH*11g (0.2 µM) were pre-incubated with NFAT (0.4 µM) for 10 mins at 25°C in the buffer (50 mM Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium Acetate, 100 ug/ml BSA, pH 7.9, 50 mM NaCl). Then FoxP3*2N (1.6 µM for IR-FKH*1g and 3.2 µM for IR-FKH*11g) was added to the mixture. Different concentration of FoxP3 was used for the two DNA
Naïve CD4+ T cells were isolated by negative selection from mouse spleens by using the isolation kit (Miltenyi Biotec) according to the manufacturer’s instructions. Cell purity was validated with >90% by FACS analysis using PE anti-CD4 (Biolegend). Cells were then activated with anti-CD3 (Biolegend), anti-CD28 (Biolegend) and 50 U/mL of IL2 (Peprotech) in complete RPMI medium (10% FBS heat-inactivated, 2 mM L-Glutamine, 1 mM Sodium Pyruvate, 100 μM NEAA, 5 mM HEPES, 0.05 mM 2-ME). Stimulation of naïve CD4+ T cells was confirmed by their increased cell sizes and expression of the activation marker CD44 (BioLegend) by FACS analysis. After 48 hours, cells were spin-infected with retrovirus containing supernatant from HEK293T cells transfected with retroviral expression plasmids (Empty MSCV-IRES-Thy1.1 vector, wildtype-FoxP3 and mutations encoding vectors) and cultured for 2–3 days in complete RPMI medium with 100 U/mL of IL2.

**CD4+ T cell cultures and retroviral transductions**

Naïve CD4+ T cells were isolated by negative selection from mouse spleens by using the isolation kit (Miltenyi Biotec) according to the manufacturer’s instructions. Cell purity was validated with >90% by FACS analysis using PE anti-CD4 (Biolegend). Cells were then activated with anti-CD3 (Biolegend), anti-CD28 (Biolegend) and 50 U/mL of IL2 (Peprotech) in complete RPMI medium (10% FBS heat-inactivated, 2 mM L-Glutamine, 1 mM Sodium Pyruvate, 100 μM NEAA, 5 mM HEPES, 0.05 mM 2-ME). Stimulation of naïve CD4+ T cells was confirmed by their increased cell sizes and expression of the activation marker CD44 (BioLegend) by FACS analysis. After 48 hours, cells were spin-infected with retrovirus containing supernatant from HEK293T cells transfected with retroviral expression plasmids (Empty MSCV-IRES-Thy1.1 vector, wildtype-FoxP3 and mutations encoding vectors) and cultured for 2–3 days in complete RPMI medium with 100 U/mL of IL2.

**Flow cytometry**

For detecting of CD25 and CTLA4 expression in transduced CD4+ T cells, activated CD4+ T cells were stained with cell surface anti-CD25 (Biolegend) and anti-CTLA4 (Biolegend) and 50 U/mL of IL2 (Peprotech) in complete RPMI medium (10% FBS heat-inactivated, 2 mM L-Glutamine, 1 mM Sodium Pyruvate, 100 μM NEAA, 5 mM HEPES, 0.05 mM 2-ME). Flow cytometry data were analyzed with FlowJo software and presented as plots of mean fluorescence intensity (MFI) of CD25 and CTLA4 in cells grouped into bins of Thy1.1 intensity. Each result is representative of 3 independent experiments.

Results were statistically analyzed using Student’s t test or a Mann-Whitney test with multiple comparisons where appropriate using Prism 6.0 (GraphPad Software, Inc). A p value of < 0.05 was considered to be statistically significant.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

For analysis of mutant mice, single cell suspensions were obtained from murine spleens after physical dissociation with a 40 μm mesh and red blood cell lysis, and from the colonic lamina propria per (Sefik et al., 2015). After Fc blocking, extracellular staining was done in ice-cold buffer (phenol red-free DMEM, 2% FBS) for 30 min using antibodies against CD45 (30-F11; BioLegend, dilution 1:200), CD4 (RM4-5; BioLegend, dilution 1:200), CD25 (PC61; BioLegend, 1:50), TCRβ (H57–597; BioLegend, 1:150), CD44 (IM7; BioLegend, dilution 1:100). Cells were then fixed overnight at 4°C using 100 μL of Fix/Perm buffer (eBioscience), followed by permeabilization using 1X permeabilization buffer (eBioscience) for 45 minutes at room temperature in the presence of the following intracellular antibodies: FoxP3 (clone FJK-16s, Invitrogen, 1:75); CTLA4/CD152 (clone UC10-4B9, BioLegend, dilution 1:200). Data was recorded on a FACSymphonyTM flow cytometer (BD Biosciences) and analyzed using FlowJo 10 software.

**FoxP3 ChIP-seq analysis**

FoxP3 ChIP-seq (Kitagawa et al., 2017; Samstein et al., 2012) data was mapped to mm10 using bowtie2 (Langmead and Salzberg, 2012) and peaks were called using HOMER with an input ChIP-seq control. Overlapping FoxP3 ChIP-seq peaks were retained and ranked by signal intensity. The top 5000 ranked FoxP3 peaks were selected for a de novo motif analysis using MEME (Bailey et al., 2015). FIMO (Grant et al., 2011) was performed to identify variations in IR-FKHM motifs based on gap size and enrichment determined for non-consensus sequences from the 548 FoxP3 ChIP-seq sequences with an observed FKHM.